Literature DB >> 9780264

Monocyte anergy in septic shock is associated with a predilection to apoptosis and is reversed by granulocyte-macrophage colony-stimulating factor ex vivo.

M A Williams1, S Withington, A C Newland, S M Kelsey.   

Abstract

The effects of priming monocytes from septic patients with granulocyte-macrophage colony-stimulating factor (GM-CSF) ex vivo were investigated. Monocytes from septic patients had depressed plasma GM-CSF and dysregulated levels of other cytokines compared with normal subjects. Membrane expression of CD71 and HLA-DR were depressed, and monocytes were anergic to lipopolysaccharide (LPS) stimulation in vitro, which was associated with spontaneous and accelerated activation-induced apoptosis by LPS. Priming monocytes with GM-CSF ex vivo augmented membrane cytokine expression, CD71, and HLA-DR. GM-CSF priming augmented cytokine secretion in response to LPS stimulation, restored cytokine secretion in monocytes from septic patients, and reversed their predilection to undergo apoptosis. Thus, monocyte dysfunction in septic shock is associated with depressed plasma levels of GM-CSF and enhanced apoptosis; however, GM-CSF stimulation ex vivo restored normal monocyte function and cytokine secretion by a mechanism that may depend on abrogating apoptosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9780264     DOI: 10.1086/314447

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

Review 1.  Sepsis-induced immunosuppression: from bad to worse.

Authors:  R C Reddy; G H Chen; P K Tekchandani; T J Standiford
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Hematopoietic stem-progenitor cells restore immunoreactivity and improve survival in late sepsis.

Authors:  Laura Brudecki; Donald A Ferguson; Deling Yin; Gene D Lesage; Charles E McCall; Mohamed El Gazzar
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

Review 3.  Mechanisms of immune resolution.

Authors:  Alfred Ayala; Chun-Shiang Chung; Patricia S Grutkoski; Grace Y Song
Journal:  Crit Care Med       Date:  2003-08       Impact factor: 7.598

4.  PATHOLOGICAL ASPECTS OF THE ANTI-INFLAMMATORY/IMMUNE SUPPRESSIVE RESPONSE IN SEPSIS AND SHOCK.

Authors:  Alfred Ayala; Yanli Ding; Rebecca J Rhee; Lesley A Doughty; Patrician S Grutkoski; Chun-Shiang Chung
Journal:  Rec Res Dev Immunol       Date:  2003-01-12

Review 5.  Blockade of apoptosis as a rational therapeutic strategy for the treatment of sepsis.

Authors:  Alfred Ayala; Doreen E Wesche-Soldato; Mario Perl; Joanne L Lomas-Neira; Ryan Swan; Chun-Shiang Chung
Journal:  Novartis Found Symp       Date:  2007

6.  Adoptive transfer of apoptotic splenocytes worsens survival, whereas adoptive transfer of necrotic splenocytes improves survival in sepsis.

Authors:  Richard S Hotchkiss; Katherine C Chang; Mitchell H Grayson; Kevin W Tinsley; Benjamin S Dunne; Christopher G Davis; Dale F Osborne; Irene E Karl
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-07       Impact factor: 11.205

Review 7.  Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression.

Authors:  Naeem K Patil; Julia K Bohannon; Edward R Sherwood
Journal:  Pharmacol Res       Date:  2016-07-25       Impact factor: 7.658

8.  Is low monocyte HLA-DR expression helpful to predict outcome in severe sepsis?

Authors:  Sara E Perry; Sobhy M Mostafa; Richard Wenstone; Alan Shenkin; Paul J McLaughlin
Journal:  Intensive Care Med       Date:  2003-05-28       Impact factor: 17.440

9.  Host immune response in sepsis due to ventilator-associated pneumonia: how is it different?

Authors:  Eirini Christaki
Journal:  Crit Care       Date:  2009-12-07       Impact factor: 9.097

10.  Decrease of CD4-lymphocytes and apoptosis of CD14-monocytes are characteristic alterations in sepsis caused by ventilator-associated pneumonia: results from an observational study.

Authors:  Aimilia Pelekanou; Iraklis Tsangaris; Antigoni Kotsaki; Vassiliki Karagianni; Helen Giamarellou; Apostolos Armaganidis; Evangelos J Giamarellos-Bourboulis
Journal:  Crit Care       Date:  2009-11-02       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.